250,000 patients to benefit from free access to short-course TB prevention treatment across seven countries
Johannesburg, 24 March 2023 – The Unitaid-funded IMPAACT4TB Consortium, led by the Aurum Institute, announced today that it will provide 250,000 patient courses of short course rifapentine-based preventive treatment regimens
Press Statement: Global Consortium welcomes reduced price for patient-friendly treatment to prevent tuberculosis
The Aurum Institute and its partners also announce the launch of the next phase of work to improve access to shorter TB prevention treatments for children and pregnant women
Johannesburg,
Partners announce reduced price for patient-friendly tuberculosis preventive treatments
August 1, 2022: Unitaid, The Aurum Institute, the Clinton Health Access Initiative (CHAI) and MedAccess today announced two new agreements to lower the price of rifapentine (RPT)-based treatments to prevent
New collaboration to research COVID-19 vaccine strategies for people living with or without HIV
Johannesburg/New York City/Oslo. 19 July 2022: The Aurum Institute, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Human Vaccines Project are partnering to deliver an important African-initiated COVID-19 vaccine
Improving availability of patient-friendly tuberculosis preventive therapy
Global partners working to tackle the tuberculosis (TB) epidemic have announced the latest in a package of measures to increase supply security and availability of a short-course TB preventive therapy
High risk of Tuberculosis in people living with HIV
The Lancet Global Health journal reports the findings of a study of a host blood test that can find those at high risk of tuberculosis in people living with HIV.
